MarkGFrattiniMDPhD
Oncology • New York, NYHematologic Oncology
Associate Professor of Medicine and Experimental Therapeutics at Columbia University Medical Center; Director of Research Hematologic Malignancies Section; Division of Hematology/Oncology New York-Presbyterian Hospital/Columbia University Medical Center
Dr. Frattini is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
622 W 168th St
New York, NY 10032Phone+1 212-305-9460Fax+1 212-305-3213
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1999 - 2002- Johns Hopkins UniversityResidency, Internal Medicine, 1997 - 1999
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1997
Certifications & Licensure
NY State Medical License 2003 - 2026
Clinical Trials
- Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2011 Sep 16
- Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2012 Dec 14
- Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML Start of enrollment: 2016 Aug 11
Publications & Presentations
PubMed
- 97 citationsMutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein, Amir T. Fathi, Olga Frankfurt
Journal of Clinical Oncology. 2021-01-01 - 1543 citationsCD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaRenier J. Brentjens, Marco L. Davila, Isabelle Riviere, Jae H. Park, Xiuyan Wang
Science Translational Medicine. 2013-03-20 - 155 citationsEnasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemiaDaniel A. Pollyea, Martin S. Tallman, Stéphane de Botton, Hagop M. Kantarjian, Robert H. Collins
Leukemia. 2019-11-01
Journal Articles
- Clonal Diversity Predicts Adverse Outcome in Chronic Lymphocytic LeukemiaVincent Miller, Tariq Mughal, Nicole Lamanna, Andrew Zelenetz, Mark L Heaney, Mark G Frattini, Nature
Abstracts/Posters
- Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution ExperienceMark G. Frattini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myelo...Mark G. Frattini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propen...Mark G. Frattini, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 8th, 2023- Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020November 5th, 2020
Lin BioScience Licenses a Novel Anti-Cancer Therapy for Hematological Malignancies and Solid Tumors from Columbia University and Memorial Sloan Kettering Cancer CenterMarch 3rd, 2017- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
